MANWIN SETS NEW PRODUCTION STANDARDS
Encourages Stricter Regulations for Producers, Performers, Agents
http://business.avn.com/articles/vid...ds-478445.html
June 12, 2012 - LUXEMBOURG - Manwin has decided to set new best practices regulations for all performers and third party producers hired to create content for its websites.
In its proposal, Manwin supports the system put in place by the APHSS, while also moving beyond the standard industry practice of 30-day interval testing.
The APHSS has set forward a best practices guideline and system that allows performers, producers, and agents to create a controlled work environment.
It includes consistent standards and guidelines for testing and treatment of adult performers, a secure database that ensures performer privacy and protects producer liability, protocol for performer support in the event of a positive HIV test result - including testing of 1st and 2nd generation partners – as well as health and safety resources provided for producers and performers.
Following months of research, and meetings with various doctors and medical experts from the most respected universities and health institutions in North America, Manwin has decided to implement additional rules for anyone involved in producing content for its sites.
The company will require FDA approved tests from the clinics listed on the APHSS.org website, specifically the HIV-1 Aptima RNA Qualitive Assay. In addition, the company will require 15-day interval testing for performers.
As of July 1st, 2012, adult entertainers performing in scenes commissioned for websites belonging to Manwin will have to provide health tests that are no older than 15 days. Manwin will pay for all additional tests needed under these new rules, in case a performer works for any of the company's brands multiple times in a 30-day period.
Manwin expects producers, performers, and agents to be in full compliance with these new regulations, and looks forward to working with the FSC in setting the highest possible standards for the industry.
---------------
The 2nd press release
MANWIN DONATES GEN PROBE APTIMA MACHINE Supports Cutting Edge Testing and Renowned Specialist
June 12, 2012 – LUXEMBOURG – Following the decision to enforce stricter health rules and guidelines for producers and performers, Manwin has decided to provide Cutting Edge Testing with support, in its bid to provide the best health services possible.
Manwin has purchased the Gen Probe Aptima machine for Cutting Edge Testing, a piece of equipment that performs the Aptima RNA Qualitive Assay.
The FDA approved test is one that Manwin requires as part of the new health standards and procedures requested from producers, performers, and agents.
While researching its new guidelines, Manwin collaborated with various North American health experts and organizations.
During this time period, Dr. Peter Miao became a great source of information and support. The renowned infectious disease expert, who was part of the original team of physicians that encountered HIV infections in 1981, oversees the Cutting Edge Testing center.
According to Dr. Miao: “Aptima testing by Gen Probe has been available for many years, and is approved by the FDA for the diagnosis of acute HIV infection. At Cutting Edge Testing, we are now transitioning to the Aptima test for screening of HIV [infections] very shortly."
Manwin is pleased to support Dr. Miao and Cutting Edge Testing.
“This demonstrates Manwin’s concern for the health and safety of all the performers and the industry as a whole,” says Dr. Miao. “By their generous gift, we now can move ahead and perform the Aptima test in the very near future.”
The company hopes that the donation will help Dr. Miao, and his team, continue their work in providing optimal health services to adult entertainment professionals, as well as the public at large.
Encourages Stricter Regulations for Producers, Performers, Agents
http://business.avn.com/articles/vid...ds-478445.html
June 12, 2012 - LUXEMBOURG - Manwin has decided to set new best practices regulations for all performers and third party producers hired to create content for its websites.
In its proposal, Manwin supports the system put in place by the APHSS, while also moving beyond the standard industry practice of 30-day interval testing.
The APHSS has set forward a best practices guideline and system that allows performers, producers, and agents to create a controlled work environment.
It includes consistent standards and guidelines for testing and treatment of adult performers, a secure database that ensures performer privacy and protects producer liability, protocol for performer support in the event of a positive HIV test result - including testing of 1st and 2nd generation partners – as well as health and safety resources provided for producers and performers.
Following months of research, and meetings with various doctors and medical experts from the most respected universities and health institutions in North America, Manwin has decided to implement additional rules for anyone involved in producing content for its sites.
The company will require FDA approved tests from the clinics listed on the APHSS.org website, specifically the HIV-1 Aptima RNA Qualitive Assay. In addition, the company will require 15-day interval testing for performers.
As of July 1st, 2012, adult entertainers performing in scenes commissioned for websites belonging to Manwin will have to provide health tests that are no older than 15 days. Manwin will pay for all additional tests needed under these new rules, in case a performer works for any of the company's brands multiple times in a 30-day period.
Manwin expects producers, performers, and agents to be in full compliance with these new regulations, and looks forward to working with the FSC in setting the highest possible standards for the industry.
---------------
The 2nd press release
MANWIN DONATES GEN PROBE APTIMA MACHINE Supports Cutting Edge Testing and Renowned Specialist
June 12, 2012 – LUXEMBOURG – Following the decision to enforce stricter health rules and guidelines for producers and performers, Manwin has decided to provide Cutting Edge Testing with support, in its bid to provide the best health services possible.
Manwin has purchased the Gen Probe Aptima machine for Cutting Edge Testing, a piece of equipment that performs the Aptima RNA Qualitive Assay.
The FDA approved test is one that Manwin requires as part of the new health standards and procedures requested from producers, performers, and agents.
While researching its new guidelines, Manwin collaborated with various North American health experts and organizations.
During this time period, Dr. Peter Miao became a great source of information and support. The renowned infectious disease expert, who was part of the original team of physicians that encountered HIV infections in 1981, oversees the Cutting Edge Testing center.
According to Dr. Miao: “Aptima testing by Gen Probe has been available for many years, and is approved by the FDA for the diagnosis of acute HIV infection. At Cutting Edge Testing, we are now transitioning to the Aptima test for screening of HIV [infections] very shortly."
Manwin is pleased to support Dr. Miao and Cutting Edge Testing.
“This demonstrates Manwin’s concern for the health and safety of all the performers and the industry as a whole,” says Dr. Miao. “By their generous gift, we now can move ahead and perform the Aptima test in the very near future.”
The company hopes that the donation will help Dr. Miao, and his team, continue their work in providing optimal health services to adult entertainment professionals, as well as the public at large.
...
Comment